

# Development of Asian Consortium for Data Collection and Clinical Trial of CNS Tumors

NCT05982691

---

Status	RECRUITING
Sponsor	National Cancer Center, Korea
Enrollment	400 participants

## Key Eligibility Criteria

---

### Inclusion (4)

- A patient who was diagnosed with CNS GCT and agreed to participate in the research between 2022-2027.
- Patients diagnosed between 2016-2022 can be enrolled if the participating institute has IRB approval for recruiting these patients as separate IRB document (Seoul Asan Hospital) or by comprehensive IRB document (Singapore NCC, Taiwan Medical University), or by recruitment on the basis of acquirement of the consent form for research (NCC, Korea).
- The age at the time of diagnosis is  $0 < \leq 40$  years
- A patient who has been diagnosed with the relevant tumor via an operation or a biopsy. In the case of CNS germinoma, a biopsy may not have been performed on a patient. In this case, the patient may register as germinoma if he or she meets the following criteria: -Germinoma is strongly suspected radiologically, and a tumor marker from serum or cerebrospinal fluid (CSF) has not increased above the institute's reference normal value; -Germinoma is suspected radiologically, and a tumor marker from serum or CSF has elevated above the institute's reference normal value (tumor markers may be AFP or hCG)

### Exclusion (1)

- The patient or the guardian of the patient did not consent to participate.

## Locations (1 total)

---

National Cancer Center, Korea, Goyang-si, Gyeonggi-do, South Korea